Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) is now available.
Venus Medtech (Hangzhou) Inc., a Hong Kong-listed mainland Chinese cardiovascular device developer, operates through entities such as wholly owned subsidiary Cardiovalve Ltd. and joint venture MTH IP, L.P. to advance its portfolio of innovative heart-related medical technologies in global markets. The company has issued a clarification announcement following media reports on a patent infringement lawsuit filed by Cardiovalve and MTH IP in the U.S. District Court for the District of Delaware against Edwards Lifesciences, stating that after reasonable inquiry it is not aware of any information requiring disclosure to prevent a false market or any inside information that must be announced under Hong Kong listing and securities regulations, and advising shareholders and potential investors to exercise caution when dealing in its shares.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a PRC-incorporated medical device company listed in Hong Kong, focused on developing and commercializing cardiovascular treatment technologies through its subsidiaries and joint ventures, including Cardiovalve Ltd. and MTH IP, L.P.
Average Trading Volume: 1,934,015
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.49B
See more insights into 2500 stock on TipRanks’ Stock Analysis page.